An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

full-length multispecific antibodies (Biclonics ® and Triclonics ®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...

Tuberculosis remains one of the deadliest infectious diseases worldwide, with drug-resistant strains posing a significant ...

The endTB trial is one of four recent randomized controlled trials testing new, shorter, and less toxic treatment regimens ...

The research, published Jan. 30 in the New England Journal of Medicine, was led by researchers at Harvard Medical School and other members of the endTB project, a collaboration among Partners In ...